NCT06284486
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
M.D. Anderson Cancer Center·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Acute Myeloid Leukemia
- Drug/Device/Intervention
- Venetoclax
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- M.D. Anderson Cancer Center
- Location
- Houston, United States of America
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Jul 31, 2024
- End date
- Dec 30, 2028
- Enrollment
- 8 participants
Primary outcome
Safety and adverse events (AEs)
Summary
To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.
ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06284486
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06284486 through Pure Global AI's free database. This Phase 2 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 8 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.